search
Back to results

Effect of Motor Rehabilitation Treatment on Amyotrophic Lateral Sclerosis (ALS) (ermoSla)

Primary Purpose

Amyotrophic Lateral Sclerosis

Status
Completed
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Standard motor rehabilitation treatment
Intensive motor rehabilitation treatment
Sponsored by
Azienda Unita' Sanitaria Locale Di Modena
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Amyotrophic Lateral Sclerosis focused on measuring Motor Rehabilitation Treatment, Intensive versus standard, Motor Disability

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosis of possible, probable or definite ALS according to the Revised El Escorial Criteria
  • Time from diagnosis <18 months at screening.
  • Forced vital capacity (FVC)> 50% at screening
  • Written informed consent

Patients will be required to take the full dose of Riluzole, but not assuming Riluzole do not constitute a criterion for exclusion.

Exclusion Criteria:

  • Enrolment in any other clinical trial in the three months prior to screening
  • Tracheostomy or NIV for> 23h/day for 14 consecutive days at screening.
  • Diagnosis of severe neurodegenerative diseases in addition to the ALS
  • Diagnosis of severe heart disease, current neoplasia, any unstable medical condition that contraindicates an intensive rehabilitation treatment
  • State of pregnancy or breastfeeding
  • Residency outside Emilia-Romagna Region
  • Lack of multidisciplinary follow-up

Sites / Locations

  • Department of Neuroscience, S. Anna Hospital
  • Department of Neuroscience, S.Agostino-Estense Hospital
  • Department of Neuroscience, IRCCS Arcispedale Santa Maria Nuova

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Standard motor rehabilitation treatment

Intensive motor rehabilitation treatment

Arm Description

Outcomes

Primary Outcome Measures

Change from Baseline in ALSFRS R

Secondary Outcome Measures

Rate of complications related to the disease: pressure sores, hospitalizations, infections
Perceived quality of care
Tracheostomy free survival
Time to supporting procedures (NIV and PEG)
Respiratory function: measured by FVC
Quality of Life: measured by McGill and ALSAQ40 scales
Disease symptoms (fatigue) measured with FSS
Depression measured by Beck Inventory Scale

Full Information

First Posted
November 21, 2014
Last Updated
August 5, 2018
Sponsor
Azienda Unita' Sanitaria Locale Di Modena
Collaborators
University of Modena and Reggio Emilia, Arcispedale Santa Maria Nuova-IRCCS, S. Anna Hospital, Azienda Unità Sanitaria Locale Reggio Emilia, Azienda Unità Sanitaria Locale Ferrara
search

1. Study Identification

Unique Protocol Identification Number
NCT02306109
Brief Title
Effect of Motor Rehabilitation Treatment on Amyotrophic Lateral Sclerosis (ALS)
Acronym
ermoSla
Official Title
Effects of Motor Rehabilitation Treatment on Disability and Quality of Life in Amyotrophic Lateral Sclerosis (ALS).
Study Type
Interventional

2. Study Status

Record Verification Date
August 2018
Overall Recruitment Status
Completed
Study Start Date
January 2015 (Actual)
Primary Completion Date
December 2017 (Actual)
Study Completion Date
April 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Azienda Unita' Sanitaria Locale Di Modena
Collaborators
University of Modena and Reggio Emilia, Arcispedale Santa Maria Nuova-IRCCS, S. Anna Hospital, Azienda Unità Sanitaria Locale Reggio Emilia, Azienda Unità Sanitaria Locale Ferrara

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
ErmoSLA is a multicentric, randomized, controlled trial to compare effects of an "intensive" or "standard" motor rehabilitation treatment on motor disability in people with ALS
Detailed Description
The study is a multicentric, randomized, controlled trial to compare effects of standard versus intensive motor rehabilitation treatment for people with ALS. Eligible patients are going to be randomly assigned to the Standard or Intensive treatment (controlling for ALSFRSR rates at enrollment, age and site of onset). Randomization ratio is 1:1. Standard treatment: 2 sessions/week of motor rehabilitation treatment (45 minutes each one) for 10 weeks for a total of 20 sessions. The program consists of exercises for aerobic endurance, reinforcement at low load and stretching. At the end of the 20 sessions patient and caregiver are going to continue activity with supervision through regular follow up. Intensive treatment is characterized by an increased volume of the above mentioned exercises: 5 sessions/week (45 minutes each one) for 10 weeks for a total of 50 sessions. At the end of the 50 sessions patient and caregiver are going to continue activity with supervision through regular follow up. Collection and analysis of data Recruitment: during the first 18 months of the study. Outcome measures: evaluated at T0-T3-T6-T9-T12-T15-T18-T21-T24. Rating scales will be administered by a neurologist in singe blind method with respect to the treatment. Data collection will be done through an ad hoc Case Report Form and entered into a database on a dedicated website.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Amyotrophic Lateral Sclerosis
Keywords
Motor Rehabilitation Treatment, Intensive versus standard, Motor Disability

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
65 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Standard motor rehabilitation treatment
Arm Type
Active Comparator
Arm Title
Intensive motor rehabilitation treatment
Arm Type
Experimental
Intervention Type
Procedure
Intervention Name(s)
Standard motor rehabilitation treatment
Intervention Description
Standard treatment: 2 sessions/week of motor rehabilitation treatment (45 minutes each one) for 10 weeks for a total of 20 sessions, including exercises for aerobic endurance, reinforcement at low load and stretching. At the end of the 20 sessions, patient and caregiver are going to continue motor activity with therapist supervision through regular follow up
Intervention Type
Procedure
Intervention Name(s)
Intensive motor rehabilitation treatment
Intervention Description
Intensive treatment is characterized by an increased exercises volume: 5 sessions/week)(45 minutes each one) for 10 weeks for a total of 50 sessions, including exercises for aerobic endurance, reinforcement at low load and stretching. At the end of the 50 sessions, patient and caregiver are going to continue motor activity with therapist supervision through regular follow up
Primary Outcome Measure Information:
Title
Change from Baseline in ALSFRS R
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Rate of complications related to the disease: pressure sores, hospitalizations, infections
Time Frame
12 months
Title
Perceived quality of care
Time Frame
12 months
Title
Tracheostomy free survival
Time Frame
12 months
Title
Time to supporting procedures (NIV and PEG)
Time Frame
12 months
Title
Respiratory function: measured by FVC
Time Frame
12 months
Title
Quality of Life: measured by McGill and ALSAQ40 scales
Time Frame
12 months
Title
Disease symptoms (fatigue) measured with FSS
Time Frame
12 months
Title
Depression measured by Beck Inventory Scale
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of possible, probable or definite ALS according to the Revised El Escorial Criteria Time from diagnosis <18 months at screening. Forced vital capacity (FVC)> 50% at screening Written informed consent Patients will be required to take the full dose of Riluzole, but not assuming Riluzole do not constitute a criterion for exclusion. Exclusion Criteria: Enrolment in any other clinical trial in the three months prior to screening Tracheostomy or NIV for> 23h/day for 14 consecutive days at screening. Diagnosis of severe neurodegenerative diseases in addition to the ALS Diagnosis of severe heart disease, current neoplasia, any unstable medical condition that contraindicates an intensive rehabilitation treatment State of pregnancy or breastfeeding Residency outside Emilia-Romagna Region Lack of multidisciplinary follow-up
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marco Vinceti, MD
Organizational Affiliation
Public Health Department, University of Modena and Reggio Emilia (IT)
Official's Role
Study Chair
Facility Information:
Facility Name
Department of Neuroscience, S. Anna Hospital
City
Ferrara
Country
Italy
Facility Name
Department of Neuroscience, S.Agostino-Estense Hospital
City
Modena
Country
Italy
Facility Name
Department of Neuroscience, IRCCS Arcispedale Santa Maria Nuova
City
Reggio Emilia
Country
Italy

12. IPD Sharing Statement

Learn more about this trial

Effect of Motor Rehabilitation Treatment on Amyotrophic Lateral Sclerosis (ALS)

We'll reach out to this number within 24 hrs